1. Home
  2. MHK vs BLCO Comparison

MHK vs BLCO Comparison

Compare MHK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mohawk Industries Inc.

MHK

Mohawk Industries Inc.

HOLD

Current Price

$135.45

Market Cap

7.3B

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.08

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHK
BLCO
Founded
1988
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Home Furnishings
Ophthalmic Goods
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
6.0B
IPO Year
1992
2022

Fundamental Metrics

Financial Performance
Metric
MHK
BLCO
Price
$135.45
$17.08
Analyst Decision
Buy
Hold
Analyst Count
9
13
Target Price
$131.00
$17.25
AVG Volume (30 Days)
790.9K
307.3K
Earning Date
02-12-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.93
N/A
Revenue
$10,785,400,000.00
$4,976,000,000.00
Revenue This Year
$0.34
$8.06
Revenue Next Year
$2.24
$5.81
P/E Ratio
$22.51
N/A
Revenue Growth
N/A
6.23
52 Week Low
$96.24
$10.45
52 Week High
$143.13
$17.86

Technical Indicators

Market Signals
Indicator
MHK
BLCO
Relative Strength Index (RSI) 70.73 49.54
Support Level $132.05 $16.60
Resistance Level $137.85 $17.45
Average True Range (ATR) 3.93 0.45
MACD 0.89 0.01
Stochastic Oscillator 90.95 53.12

Price Performance

Historical Comparison
MHK
BLCO

About MHK Mohawk Industries Inc.

Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: